Amphastar Pharmaceuticals Inc
NASDAQ:AMPH
Net Margin
Amphastar Pharmaceuticals Inc
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Net Margin Across Competitors
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| US |
|
Amphastar Pharmaceuticals Inc
NASDAQ:AMPH
|
1.1B USD |
19%
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
750.9B USD |
23%
|
|
| UK |
|
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP |
-4%
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
366.3B USD |
24%
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.9T DKK |
35%
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
208.5B CHF |
14%
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
188.9B CHF |
24%
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
158.7B GBP |
14%
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
200.5B USD |
27%
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
163.5B USD |
-126%
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
137.9B USD |
13%
|
Amphastar Pharmaceuticals Inc
Glance View
Amphastar Pharmaceuticals Inc., established in the heart of Rancho Cucamonga, California, has carved out a significant niche in the pharmaceuticals industry with its diverse portfolio centered on developing, manufacturing, and marketing generic and proprietary injectable and inhalation products. Emerging from its storied beginnings in the mid-1990s, the company’s pragmatic approach to pharmaceutical innovation emphasizes affordability and accessibility. Through strategic acquisitions and a robust in-house research and development team, Amphastar has consistently expanded its product lines, which include critical care, anti-infective, hormonal, and neuromuscular medications, seamlessly marrying clinical necessity with cost efficiency to serve both the domestic U.S. market and an expanding international clientele. Key to Amphastar's business model is its vertically integrated production process, which enables it to exercise stringent control over quality while simultaneously optimizing cost-effectiveness. The company's financial engine is fueled by its generic drug segment, where it capitalizes on the expiration of branded drug patents. By swiftly introducing generic counterparts, Amphastar taps into established demand, thus ensuring steady revenue streams. Additionally, the company's proprietary products, developed through committed R&D efforts, serve to differentiate its offerings in an otherwise commoditized sector, enabling premium pricing and fostering a competitive edge. This clever blend of generic and proprietary product strategy, paired with operational efficiency, underscores Amphastar's role as a formidable player in the pharmaceuticals market, adeptly navigating the complex landscape of regulatory compliance and healthcare trends.
See Also
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Based on Amphastar Pharmaceuticals Inc's most recent financial statements, the company has Net Margin of 19.4%.
You don't have any saved screeners yet